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Human Rhinovirus 3C protease 
cleaves RIPK1, concurrent with 
caspase 8 activation
Sarah N. Croft, Erin J. Walker & Reena Ghildyal
Human Rhinovirus (HRV) is a pathogen of significant medical importance, being a major cause of upper 
respiratory tract infections (common colds) as well as causing the majority of virus-induced asthma 
exacerbations. We investigated whether HRV could modulate apoptosis, an innate antiviral response. 
Apoptotic signals are generated either extrinsically or intrinsically and are propagated via caspase 
cascades that lead to cell death, reducing viral replication, which relies on cellular machinery. Using 
HRV16 infected cells, in combination with chemical inducers and inhibitors of extrinsic apoptosis we 
show that HRV16 3C protease cleaves a key intermediate in extrinsic apoptosis. Receptor-interacting 
protein kinase-1 (RIPK1), an extrinsic apoptosis adaptor protein, was cleaved by caspase 8, as 
expected, during chemical induction of apoptosis. RIPK1 was cleaved in HRV infection albeit at a 
different site. Caspase 8 activation, which is associated with extrinsic apoptosis, was concurrent with 
HRV 3C protease mediated cleavage of RIPK1, and potentially increased the accessibility of the HRV 
3C cleavage site within RIPK1 in-vitro. The caspase 8 mediated RIPK1 cleavage product has a pro-
apoptotic function, and further cleavage of this pro-apoptotic cleavage product by HRV 3C may provide 
a mechanism by which HRV limits apoptosis.
Human Rhinovirus (HRV) is a small virus with a single stranded, positive sense RNA genome that belongs to the 
Picornaviridae family1,2. HRV is the main viral causative agent of the common cold, and the major viral cause of 
asthma exacerbations3,4. The HRV genome encodes structural and functional proteins, of which three proteases 
(2A, 3CD and 3C) enable viral polyprotein maturation5 and have been shown to cleave host proteins. The cleavage 
of translation machinery5, transcription factors6 and nucleoporins7,8 contributes to host cell shutoff, leading to 
upregulation of viral translation and transcription. In response to viral infection, the host cell can undergo apop-
tosis, a method of controlled cell suicide that does not provoke an inflammatory response9,10. As viruses rely on 
host cellular proteins such as translation machinery for replication, initiating cell death would ultimately inhibit 
viral replication and disrupt the infection cycle11. HRV, like other Picornaviridae, is thought to be capable of reg-
ulating the apoptotic process through the activity of its proteases towards cellular apoptotic factors12,13. The delay 
or inhibition of apoptosis would allow optimal viral replication and subsequently optimal release and infection.
Extrinsic apoptosis is induced within the cell in response to external harmful stimuli and is dependent on 
the activation of caspase 814,15. Caspase 8 is recruited to the cytoplasmic portion of death receptors that have 
formed complexes with other death inducing adaptor proteins such as Fas-Associated protein with Death 
Domain (FADD), Tumor necrosis factor receptor type 1-associated Death Domain protein (TRADD)14,16 and 
Receptor-interacting protein kinase-1 (RIPK1)15,17.
RIPK1 is cleaved by caspase 8 resulting in a c-terminal fragment that functions in a pro-apoptotic manner by 
strengthening the association and interactions of the death receptor complex (15, 17, 18). Importantly, RIPK1 is 
central to the host apoptotic response to HRV infection18. Retinoic-acid Inducible Gene-I (RIG-I) and Melanoma 
Differentiation-Associated protein-5 (MDA-5) are cytoplasmic viral RNA sensors that, once activated, bind 
Interferon-β Promoter stimulator-1 (IPS-1)19,20 followed by recruitment of the proapoptotic proteins FADD and 
caspase 8. Caspase 8 is then activated through the formation of a caspase 8/RIPK1/FADD/IPS-1 complex, result-
ing in induction of the extrinsic apoptosis pathway18,21,22. Additionally, the binding of dsRNA to Toll-like receptor 
(TLR) 3 results in the recruitment of TIR-domain-containing adapter-inducing interferon-ß (TRIF) to TLR 323,24. 
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RIPK1 is bound to TRIF when complexed with TLR 3, through the RIP homotypic interaction motif (RHIM) 
domain within RIPK1 and results in caspase 8 activation through the c-terminal Death Domain of RIPK123–25.
While it is known that HRV proteases can alter cellular factors, little is known about HRV induced changes 
to apoptotic signalling processes. In the present study, we have investigated the cleavage of RIPK1 in HRV infec-
tion. RIPK1 was cleaved in cells infected with HRV16, generating a RIPK1 cleavage product that was different 
from that seen with caspase 8 cleavage. The addition of exogenous HRV 3C protease produced the same RIPK1 
cleavage product, strongly suggesting that 3C protease is responsible for the observed HRV16 specific cleavage 
of RIPK1. Additionally, inhibition of HRV 3C activity abolished viral RIPK1 cleavage. Interestingly, data from in 
vitro protease assays strongly suggest that cleavage of RIPK1 by 3C protease can occur downstream of caspase 8 
mediated RIPK1 cleavage. As caspase 8 mediated cleavage of RIPK1 is an early apoptotic event26, HRV may be 
able to limit the progression of apoptosis to its effector phase through cleavage of the pro-apoptotic, caspase 8 
generated RIPK1 cleavage product.
Results
RIPK1 is cleaved by caspase 8 in the apoptotic cascade. Treatment of O-HeLa cells with ActoD 
resulted in induction of apoptosis as evidenced by the cleavage of full length caspase 3 (Fig. 1a), as expected27; this 
was reversed with treatment with the pan-caspase inhibitor z.vad.FMK (Fig. 1a, compare lane 3 and 4). RIPK1 
was cleaved in ActoD treated cells as evidenced by the loss of full length RIPK1 and appearance of a ~38 kDa band 
(Fig. 1b, compare lane 3 with lanes 1, 2). RIPK1 cleavage was caspase dependent as addition of z.vad.FMK to 
ActoD treated cells resulted in abrogation of cleavage (Fig. 1b, compare lane 4 with lane 3). Treatment of cells with 
caspase 8 inhibitor following ActoD treatment resulted in a dose dependent reduction in RIPK1 cleavage (Fig. 1b, 
lanes 8–10); neither caspase 3 nor caspase 9 inhibitors had any effect (Fig. 1b, lanes 5–7, 11–13). Our data suggest 
that RIPK1 cleavage in ActoD induced apoptosis is dependent on caspase 8.
RIPK1 is cleaved in HRV16 infected cells. The effect of HRV16 infection on RIPK1 cleavage was investi-
gated. Cells were infected with HRV16, treated with either z.vad.FMK or specific caspase 8 inhibitor at 4 h.p.i. or 
left untreated, and lysed at indicated time-points (Fig. 1c). Uninfected cells treated with ActoD or left untreated 
served as additional controls. Cell lysates were analysed for RIPK1, with tubulin included as a loading control. 
As expected, a ~38 kDa RIPK1 caspase 8 cleavage product was observed in ActoD treated cells (lane 1). A 23 kDa 
RIPK1 cleavage product was observed in HRV16 infected cell lysates after 9 h.p.i. There was no observable change 
in 23 kDa cleavage product in presence of caspase 8 inhibitor compared to corresponding untreated lysates (com-
pare lanes 7,8 and 9,10). The cleavage of RIPK1 in HRV16 infected cells was not prevented when caspases were 
inhibited with z.vad.FMK (compare lanes 2,10). Neither the ~38 kDa nor 23 kDa RIPK1 cleavage products were 
detected in untreated, uninfected lysate (lane 11). A non-specific band of approximately ~30 kDa was present 
in all samples and is currently uncharacterised. Our data show that RIPK1 is cleaved in HRV16 infection in a 
caspase independent manner.
Inhibition of 3C protease prevents cleavage of RIPK1 in HRV16 infected cells. To determine if 
RIPK1 is cleaved by HRV16 3C, uninfected or infected O-HeLa cells were treated with ActoD to induce apoptosis 
at 3 h.p.i., alone or in combination with the HRV 3C protease inhibitor, Rupintrivir added at 9 h.p.i. Cell lysates 
were collected at 16 h.p.i, followed by Western blot analysis for RIPK1. As expected, a 23 kDa RIPK1 cleavage 
product was observed in samples subject to infection, but without treatment of Rupintrivir, correlating with a 
decrease in full length RIPK1 (Fig. 2a, lanes 4,5 in RIPK1 blots). Significantly less 23 kDa RIPK1 cleavage product 
was observed in samples treated with Rupintrivir as compared to infected samples without (compare lanes 4 and 6) 
or with (compare lanes 5 and 7) ActoD. This was confirmed by densitometric analysis of RIPK1 specific bands 
normalised to tubulin (p = 0.01 and p = 0.03 respectively, Fig. 2b).
Activity of HRV16 3C protease was clearly inhibited by Rupintrivir treatment as viral polyprotein (P1) process-
ing was downregulated; 3C protease is responsible for the cleavage of P1 to derive virus capsid proteins (VP1-4) 
(Fig. 2g)28. Rupintrivir treatment resulted in increased level of P1 (Fig. 2a, lanes 6,7 in VP2 blot) compared to 
infected cells not treated with Rupintrivir, with or without ActoD, correlating with decrease in level of 23 kDa 
RIPK1 product (lanes 6,7 in RIPK1 blot). Additional experiments showed the presence of an ~50 kDa, n-terminal 
RIPK1 cleavage product in samples subject to infection with HRV16 (Fig. 2d lanes 2 and 4) but not those subject 
to infection and treatment with Rupintrivir (Fig. 2d Lanes 6 and 8). The cleavage of RIPK1 paralleled cleav-
age of a known 3C protease substrate Poly-A-Binding protein (PABP), which was used to confirm 3C protease 
activity. Densitometric analysis of P1 specific band, normalised to tubulin showed an increase in the presence of 
Rupintrivir, compared to HRV16 infection alone (Fig. 2c), confirming the inhibition of 3C protease activity. HRV 
2A protease activity was confirmed in all infection samples, as evidenced by the virus specific cleavage of eIF4G 
(Fig. 2a, lanes 4–7, eIF4G blot) which did not parallel RIPK1 cleavage, eliminating 2A as the protease responsi-
ble for RIPK1 cleavage. The observed 2A protease activity suggests that any decrease in cleavage of RIPK1 after 
Rupintrivir treatment was not due to an overall decrease in viral protease activity. Additionally, no significant 
decrease in total viral protein synthesis was observed in samples treated with Rupintrivir as compared to corre-
sponding untreated samples (Fig. 2a).
The ~23 kDa c-terminal RIPK1 cleavage product was not directly due to induction of extrinsic apoptosis as 
it was not observed in samples treated with ActoD alone (Fig. 2a, lane 2, RIPK1 blots) and was not increased 
in infected samples treated with ActoD with or without Rupintrivir (compare lanes 5 and 7 with lanes 4 and 6 
respectively, RIPK1 blots). ActoD treatment resulted in loss of full length RIPK1 and induced apoptosis as was 
confirmed with the caspase 3 mediated degradation of eIF4G as previously described29 (lanes 2,5,7, eIF4G blot).
Amounts of active caspase 3 (17 kDa) were examined to assess any induced apoptosis in samples subject to 
infection in combination with ActoD or Rupintrivir treatment. As shown in Fig. 2d and e, there is increased 
www.nature.com/scientificreports/
3SCIEnTIfIC RepoRtS |  (2018) 8:1569  | DOI:10.1038/s41598-018-19839-4
caspase 3 activation in HRV16 infected samples treated with Rupintrivir as compared to infection only samples. 
Additionally, amounts of active caspase 3 increased with ActoD treatment as expected and increased further with 
ActoD and Rupintrivir treatment.
HRV16 3C protease cleaves RIPK1 in lung alveolar cells. To determine whether the HRV16 3C pro-
tease was able to cleave RIPK1 in lung cells, sub-confluent layers of A549 cells were transfected with GFP-tagged 
active 3C protease (GFP-3C) or an inactive mutant of 3C (GFP-3Cinac). Cell lysates were collected at 16 hours 
post transfection, followed by western blot analysis. Cleavage of a known target of 3C, PABP, was used to confirm 
activity of the 3C protease. As expected, a RIPK1 cleavage product was detected in the GFP-3C expressing sam-
ple, but not in the GFP-3Cinac or untransfected samples (Fig. 2f, compare lane 1 with lanes 2, 3 in RIPK1 blot). 
GFP-3Cinac was expressed to higher levels than GFP-3C (compare lanes 2 and 3 in the GFP blot), however, PABP 
Figure 1. ActoD induced apoptosis leads to caspase 3 activation and caspase 8-dependent RIPK1 cleavage, 
different from that seen in HRV16 infection. O-HeLa cells were either treated with ActoD at 5 µg/mL or left 
untreated. One hour post treatment, samples were treated with DMSO or indicated caspase inhibitors for 
16 hours. Cells were then lysed and proteins collected for western blot analysis. (a) Lysates of cells that were left 
untreated, treated with DMSO alone, ActoD alone or ActoD followed by z.vad.fmk were electrophoresed and 
proteins transferred to nitrocellulose membrane. Non-specific sites on the membranes were blocked with 4% 
skim milk followed by probing with anti-caspase 3 antibody (upper blot) or anti-tubulin antibody (lower blot) 
as loading control. The position of bands correlating with full length caspase 3 or tubulin is indicated on the 
right and relevant molecular weight markers (in kDa) on the left. (b) Lysates of cells that were left untreated, 
treated with DMSO alone, ActoD alone, ActoD followed by z.vad.fmk or specific caspase inhibitors were 
electrophoresed and proteins transferred to nitrocellulose membrane. After blocking non-specific sites with 
4% skim milk, membranes were probed with anti-RIPK1 antibody (upper blot) or anti-tubulin antibody (lower 
blot) as loading control. Concentrations of the specific caspase inhibitors are indicated. The position of bands 
correlating with full length RIPK1 or tubulin is indicated on the right and relevant molecular weight markers 
on the left. Cropped, relevant sections of the blots are shown for clarity, with the full length blot included in 
Supplementary Information, Figures S2 and S3. (c) O-HeLa cells were infected with HRV16 at M.O.I of 3. Cells 
were treated with caspase 8 inhibitor (4 µM) or z.vad.FMK (20 µM) at 4 h.p.i or left untreated. An uninfected 
sample was treated with ActoD (5 µg/mL) for 9 hours. Cells were lysed at indicated times (h. p. i.) and proteins 
collected for western blot analysis. Membranes were probed with anti-RIPK1 (upper blot), or anti-tubulin 
antibodies (lower blot) as loading control. Full length RIPK1 and its cleavage products (cp) are indicated on the 
left and relevant molecular weight markers on the right. *nonspecific band at ~30 kDa.
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Figure 2. HRV16 induced cleavage of RIPK1 is inhibited with treatment with Rupintrivir. O-HeLa cells 
were infected with HRV16 at an M.O.I of 3 or left uninfected, followed by treatment with ActoD (5 µg/mL) at 
3 h.p.i. and/or Rupintrivir (1 µM) at 9 h.p.i or left untreated. Cells were then lysed and proteins collected for 
western blot analysis. (a) Membrane was probed with anti-RIPK1 (c-terminal) antibody, anti-VP2 antibody, 
anti-eIF4G antibody or anti-tubulin antibody as loading control. Representative blots from one experiment 
are shown; antibodies used are indicated on the left, bands specific for P1, VP2, eIF4G, RIPK1 and tubulin are 
indicated on the right, and relevant molecular weight markers to the left of the blot. *Denotes non-specific 
bands; cp – cleavage product. (b) Band intensities of the 23 kDa viral RIPK1 cleavage product detected in a) 
were quantitated using ImageJ and normalised to tubulin. GraphPad Prism was used to ascertain statistically 
significant differences between samples treated with Rupintrivir as compared to respective infected samples. 
*p < 0.05. Data are mean +/− standard error of the mean of three independent experiments. (c) Band intensity 
representative of P1 detected in a) was quantitated using ImageJ. Results were normalised to tubulin and 
expressed as arbitrary units normalised to tubulin. Data are mean +/− standard error of the mean of three 
independent experiments. (d) Membrane was probed with anti-RIPK1 (n-terminal) antibody, anti-caspase 
3 antibody, anti-PABP antibody or anti-tubulin antibody as loading control. Representative blots from one 
experiment are shown; antibodies used are indicated on the left, bands specific for caspase 3, active caspase 
3, PABP, RIPK1 and tubulin are indicated on the right, and relevant molecular weight markers to the left of 
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was cleaved only in the GFP-3C transfected sample. Clearly, RIPK1 was cleaved in cells expressing GFP-3C but 
not -3Cinac.
Our data (Figs 1 and 2) strongly suggest that 3C protease cleaves RIPK1 in HRV16 infected cells to generate an 
~23 kDa c-terminal and an ~50 kDa n-terminal product; that 2A protease is not involved in this cleavage and that 
this cleavage is not due to cellular apoptotic response. Importantly, 3C protease cleavage of RIPK1 is observed in 
a clinically relevant alveolar cell line.
Prior cleavage of RIPK1 by caspase 8 does not abrogate 3C protease mediated cleavage 
in-vitro. We used in vitro protease assays to investigate the relationship of extrinsic apoptosis with cleavage 
of RIPK1 by 3C protease. O-HeLa cells were treated with ActoD alone to induce apoptosis or with caspase 8 
inhibitor and lysed in the absence of protease inhibitors. The lysates were incubated with HRV14 3C (poly His 
tagged) protease for 6 hours followed by Western blot analysis. A 23 kDa RIPK1 cleavage product was observed 
only in samples treated with 3C protease (Fig. 3a, lanes 2, 4, 6, RIPK1 blot), suggesting that 3C protease can cleave 
RIPK1 giving rise to the product observed in HRV16 infection. Induction of apoptosis by ActoD prior to 3C pro-
tease assay resulted in increased cleavage (increased 23 kDa cleavage product relative to tubulin, lane 4); this was 
reduced by caspase 8 inhibitor (lane 6). Quantitation of the 3C induced RIPK1 cleavage product supports these 
observations, with HRV16 3C dependent cleavage of RIPK1 up regulated in ActoD treated cells, as compared to 
untreated control and a significant reduction of cleavage in samples treated with ActoD and caspase 8 inhibitor 
prior to 3C protease assay (Fig. 3b; p = 0.007 ActoD + 3C vs ActoD + caspase 8 inhibitor + 3C).
The data in Fig. 3 confirms that RIPK1 cleavage in HRV infected cells is mediated by 3C protease. Additionally, 
induction of apoptosis did not abrogate this cleavage; indeed caspase 8 activity may facilitate the cleavage of 
RIPK1 by 3C protease.
Apoptosis induction reduces viral replication. We next investigated whether inhibition of apoptosis, 
and specifically caspase 8, had an effect on viral replication. HRV16 infected cells were treated with ActoD with 
or without caspase 8 inhibitor 1 hour later, or with caspase 8 inhibitor alone and infectious virus titres measured 
at 24 h.p.i. Viral titres were significantly reduced by ActoD treatment (p = 0.0277) and caspase 8 inhibitor alone 
(p = 0.0387) but this reduction was not observed when caspase 8 activity was inhibited after ActoD treatment 
(Fig. 4a). However, viral titres were non-significantly increased in HRV16 infected cells treated with ActoD fol-
lowed by caspase 8 inhibitor compared to HRV16 infected cells treated with ActoD alone.
HRV16 infection alters ActoD induced cell death. O-HeLa cells were left untreated (con-
trol), infected with HRV16, treated with ActoD to induce apoptosis, or infected with HRV16, then 
treated at 3 h.p.i. Cells were harvested at 12 h.p.i. and subjected to Annexin V-FITC labelling (apopto-
sis) and Pi staining (necrosis) followed by flow cytometry. Control cells, as expected were mostly healthy 
(Fig. 4b,c, >80% negative for Annexin V or Pi), with a small population (<10%) showing signs of necro-
sis (positive for Pi) or late apoptosis (positive for both Annexin V and Pi). ActoD treatment alone resulted 
in increased apoptosis, as expected, with ~50% cells showing signs of apoptosis (positive for Annexin V 
only or both Annexin V and Pi); there were ~10% necrotic cells (positive for Pi only). Infection with HRV16 
resulted in ~30% of cells in early or late apoptosis (positive for Annexin V only or both Annexin V and Pi) 
and negligible necrotic cells. ActoD treatment in the presence of HRV16 infection did not result in lat 
e apoptosis, with cells equally divided between healthy and early apoptotic phenotypes (Fig. 4b, compare cell 
scatter plot labelled ActoD with that labelled HRV16+ ActoD). The percentage of cells present in each quadrant 
for the control, ActoD treatment and ActoD+ HRV16 infection are shown in Fig. 4c. These results confirm that 
ActoD treatment in the presence of HRV16 infection causes reduced late apoptosis (An+/Pi+) and necrosis 
(An−/Pi+) with an increase in early apoptosis (An+/Pi−) compared to treatment with ActoD alone.
Our data in Fig. 4 show that apoptosis progression, as induced by continued treatment with ActoD, is det-
rimental to HRV16, and leads to reduction in infectious titres. However, in the presence of HRV16 infection, 
ActoD is restricted from causing the full effects of apoptosis, suggesting that HRV16 is able to contain apoptosis 
progression.
the blot. (e) Band intensity representative of active caspase 3 (17 kDa) detected in d) was quantitated using 
ImageJ. Results were normalised to tubulin and expressed as arbitrary units normalised to tubulin. Data 
are mean +/− standard error of the mean of three independent experiments. (f) GFP-3C (active) or GFP-
3Cinac (inactive) constructs were transfected into a sub-confluent monolayer of A549 cells. At 16 hours 
post-transfection cells were lysed and proteins collected. Cell lysates were then processed for western blot 
analysis. Membrane was probed with primary anti-RIPK1 (n-terminal) antibody, with anti-tubulin antibody 
included as a loading control. Primary anti-PABP antibodies were included to validate activity or inhibition 
of viral proteases. Anti-GFP antibodies were included to confirm transfection. Proteins were detected with 
ECL. Molecular weight markers are to the left of the blot. The image is representative of three independent 
experiments. Cropped, relevant sections of the blots are shown for clarity, with the full length blot included in 
Supplementary Information, Figures S4 and S5. (g) Schematic diagram depicting HRV polyprotein processing 
into mature proteins. Translation of RNA genome into a large single polyprotein is followed by the 2A mediated 
cleavage (unfilled triangle) between P1 and P2 protein regions. Subsequent cleavages are mediated by the 3C 
protease (grey triangles) or by autocatalysis (no triangle).
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Discussion
The data presented in the current study indicates that HRV16 modulates the induction of extrinsic apoptosis in 
infected cells by cleaving RIPK1, a key apoptosis intermediate induced in response to HRV infection, and that this 
cleavage is accomplished by 3C protease.
RIPK1 was cleaved in cells infected with HRV16, however, in contrast to the 38 kDa product produced by 
caspase 8 cleavage (Fig. 1b), a c-terminal 23 kDa cleavage product is produced during HRV16 infection (Figs 1c 
and 2a). Figure 2c shows an additional RIPK1 band at ~30 kDa, it is present in all samples and further work is 
required to elucidate its function/relevance. The addition of the 3C protease inhibitor Rupintrivir led to a reduc-
tion in the c-terminal 23 kDa cleavage product seen in infection (Fig. 1c), suggesting that HRV16 3C protease is 
responsible for the virus-induced RIPK1 cleavage product. It is unlikely that HRV16 2A protease is responsible for 
cleavage of RIPK1, as HRV16 2A protease activity was still observed in Rupintrivir treated samples (Fig. 2a, eIF4G 
blot), while 3C protease activity was decreased, as evidenced by a lack of viral polyprotein maturation (Fig. 2a, P1 
band in the VP2 blot).
The in vitro addition of the HRV 3C protease to whole cell lysate resulted in the same c-terminal 23 kDa RIPK1 
cleavage product (Fig. 3a), further confirming that HRV 3C is likely the viral protease responsible for cleavage 
of RIPK1 during HRV16 infection and this was confirmed to be the c-terminal of RIPK1 (Fig. S2). Additionally, 
transfection of a GFP-3C construct into lung alveolar cells resulted in the same viral-induced cleavage of RIPK1 as 
seen in previous experiments performed in O-HeLa cells (Fig. 2f), indicating this is not a cell line specific event.
Most viruses rely on the cellular processes of a viable cell for their replication and assembly and as such, induc-
tion of apoptosis disrupts viral replication and limits infection30. The initiation of extrinsic apoptosis can occur 
via a number of receptors including the dsRNA sensors RIG-I, TLR-3 and MDA-5, which upon activation lead to 
the formation of an apoptosis signalling death complex10. Caspase 8 is recruited to this complex and is autophos-
phorylated, inducing autocleavage and activation31. The activation of caspase 8 has immediate effects such as the 
Figure 3. HRV 3C protease cleaves RIPK1 to produce a 23 kDa cleavage product. O-HeLa cells were either 
treated with ActoD and/or caspase 8 inhibitor (1 hour post ActoD treatment) or remained untreated as 
indicated. Cells were lysed 9 hours later and proteins collected. HRV 3C was added where indicated and samples 
were incubated for 6 hours before stopping the protease reaction. Cell lysates were then processed for western 
blot analysis. (a) Membrane was probed with anti-RIPK1 (c-terminal) antibody, anti-poly His antibody with 
anti-tubulin antibody included as loading control. (b) Band intensity representative of HRV 3C induced 23 kDa 
RIPK1 cleavage product detected in a), was quantitated using ImageJ. Results were normalised to tubulin 
and expressed as arbitrary units. Experiments were repeated three times and relative protein intensities are 
represented as mean +/− standard error of the mean. *p ≤ 0.05. Cropped, relevant sections of the blots are 
shown for clarity, with the full length blot included in Supplementary Information, Figure S6.
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cleavage of RIPK115. RIPK1 is a serine-threonine kinase that in its full length form promotes a pro-inflammatory 
response to specific cytokines15. Full length RIPK1 sustains a pro-survival or pro-inflammatory signal through 
NF-kB activation and interferes with FADD and TRADD interactions15. The caspase 8 dependent cleavage of 
RIPK1 during apoptosis inhibits the pro-survival/inflammatory effects, and the generated c-terminal 38 kDa 
cleavage product enhances interactions between death receptor-associated adaptor proteins FADD/TRADD, 
thus sensitising the cell to extrinsically induced apoptosis15. Using in vitro protease assays, we show that initial 
Figure 4. (a) HRV16 replication is down regulated with inhibition of caspase 8. O-HeLa cells were infected 
with HRV16 at an M.O.I of 3. At 3 h.p.i., ActoD (5 µg/mL) was added to selected samples. Caspase 8 was 
inhibited as indicated through addition caspase 8 inhibitor (4 µM) at 4 h.p.i. Cultures were frozen at 24 h.p.i. 
Once thawed, virus was clarified and titrated. Results are expressed as mean of 3 independent experiments. 
Error bars are +/− standard error of the mean. *p ≤ 0.05, ns – nonsignificant. (b) HRV16 restricts apoptotic 
pathways. O-HeLa cells were infected and treated with ActoD as in a) above. Cells were collected at 12 h.p.i and 
the effect of treatment and/or infection analysed by flow cytometry after staining with annexin V-FITC (An) 
and propidium iodide (Pi). Representative dual-parameter fluorescence density blots were acquired. (c) Bars 
are representative of percentage of viable (An−/Pi−), early apoptotic (An+/Pi−), late apoptotic (An+/Pi+) or 
necrotic (An−/Pi+) cells of total number of cells within each sample.
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induction of extrinsic apoptosis may promote 3C protease cleavage of RIPK1 (Fig. 3b), as cell lysates treated with 
ActoD alone showed an increase in RIPK1 cleavage compared to untreated and caspase 8 inhibitor treated lysates. 
The 3C mediated cleavage of RIPK1 in lysates treated with ActoD was also increased, albeit non-significantly, as 
compared to untreated lysates. These results suggest that caspase 8 cleavage of RIPK1 may induce a conforma-
tional change in RIPK1, subsequently allowing greater accessibility to the HRV 3C cleavage site. The upregulation 
of viral cleavage of RIPK1 with caspase 8 activation was not seen in the infection models (Fig. 2b). This difference 
may be due to an increased accessibility of RIPK1 during the cell lysis process, however the prior cleavage of 
RIPK1 by caspase 8 did not abolish HRV cleavage, indicating that the two cleavage events do not negate each 
other.
As the caspase 8 inhibitor alone reduced viral titre (Fig. 4a) it could be proposed that some caspase 8 activation 
is beneficial to viral replication. However, the down regulation of viral replication with induction of apoptosis is 
widely reported11,32, and as expected26, prolonged activation of caspase 8 (ActoD treatment alone) commits the 
cell to the apoptotic pathway with coincident reduction in HRV infectious titre (Fig. 4a). However the addition 
of a specific caspase 8 inhibitor 1 hour after apoptosis induction led to an almost normal level of infectious virus 
titre (Fig. 4a); this is in agreement with a previous report33, suggesting that some caspase activation is required 
for effective virus replication. These data also suggest that the early pro-apoptotic effects of caspase 8 activation 
are not deleterious to virus replication. Interestingly, there was an increase in viral protein expression (VP2) 
with ActoD treatment (Fig. S1), suggesting that the induction of extrinsic apoptosis inhibits viral assembly or 
release but doesn’t inhibit viral protein synthesis. This indicates that the decrease in virus titre was not due to 
any decrease in viral protein synthesis and further suggests that a decrease in viral titre is most likely due to the 
apoptotic effects of ActoD.
Further evidence of HRV-induced changes to apoptotic pathways is observed in the flow cytometry results 
(Fig. 4b and c), which demonstrate a clear shift in the apoptotic state of cells. The treatment of cells with ActoD 
led to an increase in early and late apoptotic cells compared to the control, as expected. In contrast the proportion 
of late apoptotic cells is decreased with HRV16 infection of ActoD cells (Fig. 4b and c), with a coincident increase 
in the proportion of cells in early apoptosis as compared to ActoD alone (Fig. 4c). Together this suggests that the 
apoptotic pathways induced by ActoD did not to proceed into a late apoptotic state when cells are infected with 
HRV16 for 12 hours, probably due to viral restriction of apoptosis. Furthermore, the amount of caspase 3 acti-
vation in cells infected with HRV16 and treated with ActoD was increased with Rupintrivir treatment (Fig. 2e), 
further strengthening the proposed role of the 3C protease in antagonising apoptosis pathways.
As induction of apoptosis reduces production of infectious virus particles, it can be deduced that subsequent 
cleavage of apoptotic factors by HRV would facilitate viral production; indeed Picornaviridae proteases have pre-
viously been implicated in cleaving MDA-5 and RIG-I13,34 both of which have apoptosis inducing effects through 
caspase activation and recruitment domains. An essential adaptor protein, IPS-1, that facilitates the association 
of RIG-I and MDA-5 complexes, is also cleaved by Picornaviridae 3C and 2A proteases13,34,35, suggesting a mecha-
nism by which induction of a host immune response is suppressed by Picornavirus. The TLR-3 and RIPK1 adap-
tor protein TRIF is also cleaved in coxsackievirus B infection35, further identifying the importance of disrupting 
these apoptotic pathways for Picornavirus infection. The common modulation of these pro-apoptotic proteins 
supports the data presented herein, that the cleavage of RIPK1 by HRV is imperative to changing host responses 
and establishing viral infection. Furthermore, inhibition of apoptosis may be a common attribute of picornavi-
ruses; in addition to the examples above, procaspase 9 is cleaved by poliovirus in vitro36.
Modulation of RIPK1 specifically may be a mechanism by which HRV modifies apoptotic pathways, confer-
ring a cellular environment advantageous for viral replication. This hypothesis is supported by in silico sequence 
analysis of RIPK1 that showed a predicted HRV 3C cleavage site at Glutamine 43037, downstream of the caspase 
8 cleavage site (Aspartic acid 324)15, potentially generating a ~25 kDa c-terminal RIPK1 product and a ~50 kDa 
n-terminal RIPK1 product, similar to that observed in this study. Throughout this study, two RIPK1 antibodies 
were used; the n-terminal RIPK1 antibody detected full length RIPK1 and a 50 kDa cleavage product (Fig. 2d and f) 
and the c-term antibody used detected full length RIPK1 and a 23 kDa cleavage product (Figs 1b,c, 2a and 3a). As 
described in this model (Fig. 5), the cleavage of RIPK1 at Glutamine 430 may disrupt the pro-apoptotic activity 
of the caspase 8 generated c-terminal RIPK1 fragment; supported by our data that the cell death profile (Fig. 4b) 
of ActoD treated cells differed between HRV16 infected and uninfected cells. Additional mechanistic studies are 
required to confirm the link between RIPK1 cleavage and the alteration of cell death pathways.
Together, our data suggest a scenario wherein initial induction of extrinsic apoptosis and cleavage of RIPK1 
by caspase 8 in response to HRV infection may be prevented from proceeding to full apoptosis by cleavage of 
the pro-apoptotic RIPK1 fragment by HRV 3C protease. The 3C cleavage site and whether RIPK1 is a common 
substrate of all HRV subtypes remains to be elucidated.
Figure 5. Proposed model of RIPK1 cleavage by HRV 3C within the caspase 8 generated, pro-apoptotic RIPK1 
fragment. RIPK1 is cleaved by caspase 8 at Aspartic acid 324, inducing formation of a c-terminal, pro-apoptotic 
RIPK1 fragment early in apoptosis (19). HRV16 3C cleavage is predicted to occur at Glutamine 430, within the 
caspase 8 generated cleavage product and may generate an anti-apoptotic RIPK1 cleavage product.
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Methods
Reagents. Actinomycin D (ActoD) (Sigma-Aldrich) was used at a concentration of 5 µg/mL to induce 
apoptosis. The pan-caspase inhibitor z.vad.FMK (BD Pharmigen) was used at concentration of 20 µM. Caspase 
inhibitors were purchased from Calbiochem and used at 4 µM (caspase 8 inhibitor) or as indicated. DMSO only 
controls were used to account for any cellular or viral alterations induced by the drug vehicle. The HRV 3C 
protease inhibitor, Rupintrivir (Santa Cruz, SC-208317) was added to infected cells at 1 µM as indicated. Anti-
RIPK1 (ThermoScientific, 1860909) or anti-RIPK1 n-terminal (Cell signalling 3493) antibodies were used to 
detect full length RIPK1 and its cleavage products. Antibodies to caspase 3 (9662), Poly(A)-binding protein 
(PABP, 4992) and tubulin (2148) were purchased from Cell Signalling Technologies. Antibodies to poly-histidine 
tag (11922416001) Green Fluorescent protein (GFP, 11814460001) were purchased from Roche. Viral protein 
expression was detected with anti-VP2 antibody (QED Biosciences, 18758). Rabbit polyclonal antibody to eIF4G 
(sc11373) was purchased from Santa Cruz.
Cells and virus. A549 cells (ECACC: 86012804) were used for all transfections and maintained in Dulbecco’s 
modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and Penicillin, Streptomycin 
and Neomycin (PSN, Gibco).
Ohio-HeLa (O-HeLa) cells (ECACC: 84121901) were used for infections throughout this study and main-
tained in DMEM supplemented with 10% FBS and PSN. All apoptosis or viral replication experiments were con-
ducted in DMEM supplemented with 2% FBS and PSN. HRV serotype 16 was used for all experiments. HRV16 
was cultured in O-HeLa cells as previously described38. Subconfluent monolayers of O-HeLa cells were infected 
with HRV16 at a multiplicity of infection (M.O.I) of 3 by absorption for 1 hour with occasional rocking, then 
removal of viral inoculum and replacement with DMEM supplemented with 2% FBS and PSN. Cells were treated 
with ActoD at 3 hours post infection (h.p.i) for 6 hours, z.vad.FMK at 4 h.p.i for 5 hours, caspase 8 inhibitor at 
4 h.p.i for 5 hours or Rupintrivir at 9 h.p.i. for 7 hours. At indicated timepoints, cells were washed once with phos-
phate buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.7 mM KH2PO4, H2O (pH 7.4)) and 
incubated in RIPA buffer (150 mM NaCl, 1% triton-X, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris-HCl 
with phosphatase and protease inhibitors (Roche)) for 30 minutes on ice. Cell lysates were collected and cen-
trifuged at 12,000 rpm for 10 minutes to remove cell debris. Supernatant was collected and Laemmli buffer was 
added before heating at 90 °C for 5 minutes as previously described38. Cell lysates were processed for Western blot 
analysis as described below.
In vitro Protease Assay. Sub-confluent O-HeLa cells were treated with combinations of ActoD, z.vad.
FMK or caspase 8 inhibitor (1 hour post ActoD treatment) or left untreated as indicated, and incubated for a 
total of 6 hours. Cells were lysed and proteins collected in RIPA buffer (without inhibitors) as described above. 
Lysates were incubated with 4U of recombinant HRV14 3C protease for 6 hours at 30 °C. The reaction was stopped 
with heating in Laemmli buffer for 5 minutes at 90 °C. Samples were then processed for Western Blot analysis as 
described below.
Transfection. Previously described38 constructs encoding GFP tagged active HRV 3C protease (GFP-3C) 
or the inactive 3C protease (GFP-3Cinac) were transfected into a subconfluent monolayer of A549 cells with 
Lipofectamine 2000 reagent (Thermofisher) as per manufacturer’s instructions. At 16 hours post transfection, 
transfected cells or untransfected control cells were washed once with PBS, lysed in RIPA buffer as described 
above and processed for Western Blot as described below.
Western Blot analysis. Cell lysates were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
on 12.5% polyacrylamide gels and transferred to nitrocellulose membrane in Tris-Glycine-ethanol buffer (25 mM 
Tris Base, 192 mM Glycine, 20% Ethanol) for 90 minutes at 400mAmps. Transfer of proteins was confirmed with 
staining with Ponceau S Red (Sigma). Nonspecific binding sites were blocked with 4% skim milk or BSA in PBS. 
Blots were incubated overnight at 4 °C in primary antibody diluted in 1% skim milk or BSA in PBST (PBS with 
0.1% Tween 20). After overnight incubation blots were washed in PBST and incubated in species specific second-
ary antibody conjugated to horseradish peroxidase diluted 1:5000 in 1% skim milk in PBST. Bound antibodies 
were detected with Enhanced Chemiluminiscence (ECL, Perkin Elmer) and exposure on Li-Cor Odyssey Fc 
Imager. Where appropriate, digital images were analysed using ImageJ to estimate protein levels relative to tubu-
lin and values expressed as arbitrary units normalised to tubulin.
Viral Replication kinetics. Sub-confluent O-HeLa cells were infected with HRV16 at M.O.I of 3 by absorp-
tion for 1 hour with occasional rocking, followed by replacement of inoculum with DMEM supplemented with 
2% FBS and PSN. At 3 h.p.i cells were treated with ActoD at 5 µg/mL or remained untreated, as indicated. At 
4 h.p.i either z.vad.FMK (20 µM) or caspase 8 inhibitor (4 µM) were added, as indicated. At indicated timepoints, 
cultures were frozen at −80 °C. Samples were thawed at room temperature and centrifuged to remove cellular 
debris, followed by titration as previously described38.
The viral titre was calculated as mean of three titres for each condition as determined by the Reed and Muench 
Calculator39. Viral titres are expressed as mean+/− standard error of the mean (SEM).
Flow Cytometry Apoptosis Assay. O-HeLa cells were infected with HRV16 at M.O.I of 3 as described above 
or left untreated. At 3 h.p.i cells were treated with ActoD at 5 µg/mL or left untreated. Cells were collected and resus-
pended in Annexin V binding buffer (HEPES; 10 mM, NaCl; 140 mM, CaCl2; 2.5 mM) and stained with Annexin 
V-FITC conjugate (ThermoFisher: A13199) and Propidium Iodide (Pi) (BD: 556463) before flow cytometric analysis 
as per manufacturer’s instructions. BD LSRII cytometer and BD FACSDiva 8.0.1 were used for data acquisition.
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Statistical Analysis. Graphpad Prism 6 was used to determine statistical significance between relative esti-
mated protein levels normalised to tubulin. Unless indicated otherwise, experiments were repeated three times 
and statistical significance was determined with a 2-tailed unpaired t-test, assuming equal variance of standard 
deviation. Statistical significance was accepted at p < 0.05.
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